化学 - 多元化

Search documents
Avient (AVNT) Tops Q2 Earnings and Revenue Estimates
ZACKS· 2025-08-01 12:21
Core Viewpoint - Avient (AVNT) reported quarterly earnings of $0.8 per share, exceeding the Zacks Consensus Estimate of $0.78 per share, and showing an increase from $0.76 per share a year ago, indicating a positive earnings surprise of +2.56% [1] Financial Performance - The company achieved revenues of $866.5 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.78% and showing growth from $849.7 million year-over-year [2] - Over the last four quarters, Avient has consistently surpassed consensus EPS estimates four times and topped revenue estimates two times [2] Stock Performance and Outlook - Avient shares have declined approximately 22.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.8% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.67 for the coming quarter and $2.76 for the current fiscal year [7] Industry Context - The Zacks Chemical - Diversified industry, to which Avient belongs, is currently ranked in the bottom 5% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - The performance of Avient's stock may also be influenced by the overall industry outlook, as historical data indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]
Methanex (MEOH) Q2 Earnings Beat Estimates
ZACKS· 2025-07-30 23:26
Methanex (MEOH) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +130.95%. A quarter ago, it was expected that this methanol supplier would post earnings of $1.25 per share when it actually produced earnings of $1.3, delivering a surprise of +4%.Over the last four quarters, the company ...
Tronox (TROX) Reports Q2 Loss, Lags Revenue Estimates
ZACKS· 2025-07-30 22:55
Core Viewpoint - Tronox reported a quarterly loss of $0.28 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.04, marking an earnings surprise of -600% [1] - The company has consistently missed consensus EPS estimates over the last four quarters, with revenues of $731 million for the quarter ended June 2025, falling short of the Zacks Consensus Estimate by 5.98% [2] Financial Performance - The quarterly loss of $0.28 per share compares to earnings of $0.07 per share a year ago, indicating a substantial decline in profitability [1] - Revenues decreased from $820 million in the same quarter last year to $731 million, reflecting a year-over-year decline [2] Stock Performance - Tronox shares have declined approximately 45.2% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [3] - The stock currently holds a Zacks Rank of 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $779.62 million, while the estimate for the current fiscal year is $0.04 on $3 billion in revenues [7] - The trend of estimate revisions for Tronox has been unfavorable leading up to the earnings release, which may impact future stock performance [6] Industry Context - The Chemical - Diversified industry, to which Tronox belongs, is currently ranked in the bottom 5% of over 250 Zacks industries, suggesting a challenging environment for the company [8] - The performance of Tronox's stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]
Strength Seen in Albemarle (ALB): Can Its 7.2% Jump Turn into More Strength?
ZACKS· 2025-07-09 12:41
Company Overview - Albemarle (ALB) shares increased by 7.2% to $70.22 in the last trading session, with a higher-than-average trading volume, compared to a 5.1% gain over the past four weeks [1] - Jefferies analyst slightly lowered the price target for Albemarle from $85 to $84 while maintaining a "Buy" rating, indicating continued confidence in the stock's growth potential despite the revision [1] Earnings Expectations - Albemarle is expected to report a quarterly loss of $0.80 per share, reflecting a year-over-year change of -2100%, with revenues projected at $1.21 billion, down 15.5% from the previous year [2] - The consensus EPS estimate for Albemarle has been revised 1.1% lower over the last 30 days, and a negative trend in earnings estimate revisions typically does not lead to price appreciation [3] Industry Comparison - Albemarle belongs to the Zacks Chemical - Diversified industry, where another company, Akzo Nobel NV (AKZOY), closed the last trading session 1.5% higher at $23.81, with a 4.2% return over the past month [3] - AkzoNobel's consensus EPS estimate for the upcoming report remains unchanged at $0.47, representing a year-over-year change of +23.7%, and it currently holds a Zacks Rank of 2 (Buy) [4]
LSB (LXU) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-04-29 23:05
Company Performance - LSB reported a quarterly loss of $0.02 per share, matching the Zacks Consensus Estimate, compared to earnings of $0.12 per share a year ago, representing an earnings surprise of -200% [1] - The company posted revenues of $143.43 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 7.04%, and an increase from year-ago revenues of $138.2 million [2] - Over the last four quarters, LSB has surpassed consensus EPS estimates just once, but has topped consensus revenue estimates three times [2] Stock Performance - LSB shares have declined approximately 22.4% since the beginning of the year, while the S&P 500 has decreased by 6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.23 on $154 million in revenues, and $0.27 on $551.05 million in revenues for the current fiscal year [7] Industry Outlook - The Zacks Industry Rank for Chemical - Diversified is currently in the bottom 15% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact LSB's stock performance [5]